Vygenerované: 10.03.2026 06:12:49
Súhrn: - Home - Medical news & Guidelines - Anesthesiology - Cardiology and CTVS - Critical Care - Dentistry - Dermatology - Diabetes and Endocrinology - ENT - Gastroenterology - Medicine - Nephrology - Neurology - Obstretics-Gynaecology - Oncology - Ophthalmology - Orthopaedics - Pediatrics-Neonatology - Psychiatry - Pulmonology - Radiology - Surgery - Urology - Laboratory Medicine - Diet - Nursing - Paramedical - Physiotherapy - Health news - Fact Check - Bone Health Fact Check - Brain Health Fact Check - Cancer Related Fact Check - Child Care Fact Check - Dental and oral health fact check - Diabetes and metabolic health fact check - Diet and Nutrition Fact Check - Eye and ENT Care Fact Check - Fitness fact check - Gut health fact check - Heart health fact check - Kidney health fact check - Medical education fact check - Men's health fact check - Respiratory fact check - Skin and hair care fact check - Vaccine and Immunization fact check - Women's health fact check - AYUSH - State News - Andaman and Nicobar Islands - Andhra Pradesh - Arunachal Pradesh - Assam - Bihar - Chandigarh - Chattisgarh - Dadra and Nagar Haveli - Daman and Diu - Delhi - Goa - Gujarat - Haryana - Himachal Pradesh - Jammu & Kashmir - Jharkhand - Karnataka - Kerala - Ladakh - Lakshadweep - Madhya Pradesh - Maharashtra - Manipur - Meghalaya - Mizoram - Nagaland - Odisha - Puducherry - Punjab - Rajasthan - Sikkim - Tamil Nadu - Telangana - Tripura - Uttar Pradesh - Uttrakhand - West Bengal - Medical Education - Industry Adding Fourth Oral Drug Beats Metformin Dose Escalation in Uncontrolled Type 2 Diabetes: EFFORT Trial South Korea: A new multicenter clinical trial published in Diabetes, Obesity & Metabolism suggests that intensifying treatment with a fourth oral antidiabetic agent may provide superior glycaemic control compared with simply increasing the dose of metformin in patients with type 2 diabetes inadequately controlled on triple oral therapy The study, titled the EFFORT trial, was led by Dr - A total of 193 participants were analyzed, including 145 in the quadruple therapy group and 48 in the metformin dose-escalation group.
Doplnenie: - A total of 193 participants were analyzed, including 145 in the quadruple therapy group and 48 in the metformin dose-escalation group.
Súhrn: - Home - Medical news & Guidelines - Anesthesiology - Cardiology and CTVS - Critical Care - Dentistry - Dermatology - Diabetes and Endocrinology - ENT - Gastroenterology - Medicine - Nephrology - Neurology - Obstretics-Gynaecology - Oncology - Ophthalmology - Orthopaedics - Pediatrics-Neonatology - Psychiatry - Pulmonology - Radiology - Surgery - Urology - Laboratory Medicine - Diet - Nursing - Paramedical - Physiotherapy - Health news - Fact Check - Bone Health Fact Check - Brain Health Fact Check - Cancer Related Fact Check - Child Care Fact Check - Dental and oral health fact check - Diabetes and metabolic health fact check - Diet and Nutrition Fact Check - Eye and ENT Care Fact Check - Fitness fact check - Gut health fact check - Heart health fact check - Kidney health fact check - Medical education fact check - Men's health fact check - Respiratory fact check - Skin and hair care fact check - Vaccine and Immunization fact check - Women's health fact check - AYUSH - State News - Andaman and Nicobar Islands - Andhra Pradesh - Arunachal Pradesh - Assam - Bihar - Chandigarh - Chattisgarh - Dadra and Nagar Haveli - Daman and Diu - Delhi - Goa - Gujarat - Haryana - Himachal Pradesh - Jammu & Kashmir - Jharkhand - Karnataka - Kerala - Ladakh - Lakshadweep - Madhya Pradesh - Maharashtra - Manipur - Meghalaya - Mizoram - Nagaland - Odisha - Puducherry - Punjab - Rajasthan - Sikkim - Tamil Nadu - Telangana - Tripura - Uttar Pradesh - Uttrakhand - West Bengal - Medical Education - Industry MASLD in T2D: Why Weight Loss Is More Than Cosmetic? India's diabetes burden is escalating rapidly, with 101 million adults currently living with T2DM (ICMR-INDIAB Study) Compounding this crisis, MASLD-strongly associated with T2DM and metabolic syndrome — affects 68 2% of Indian T2DM patients, making consideration of hepatic steatosis as an urgent, underrecognized complication demanding immediate clinical attention.
Doplnenie: MASLD in T2D - Associated Risks & How Obesity Further Adds Trouble? Co-existing MASLD in T2DM significantly accelerates progression to advanced fibrosis, hepatic decompensation, and hepatocellular carcinoma, while simultaneously amplifying the risk of macro- and microvascular complications.